RECURSION PHARMACEUTICALS, INC. (RXRX) has 17 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 4 sales totalling $435K. Most recent filing: Sept. 16, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 16, 2026 filed Sept. 15, 2026 | Taylor Ben R Chief Financial Officer | $18,400 | 5,396 | −1% | No | |
|
|
||||||
| Sept. 10, 2026 filed Sept. 8, 2026 | Khan Najat CEO and President | −$78,822 | 22,408 | −1% | Yes | |
|
|
||||||
| Sept. 2, 2026 filed Sept. 1, 2026 | Borgeson Blake Director | −$100,200 | 30,000 | −0% | Yes | |
|
|
||||||
| Aug. 18, 2026 filed Aug. 17, 2026 | Hallett David Chief Scientific Officer | $84,236 | 26,657 | −2% | No | |
|
|
||||||
| Aug. 18, 2026 filed Aug. 17, 2026 | Taylor Ben R Chief Financial Officer | $79,057 | 25,018 | −2% | No | |
|
|
||||||
Showing the 5 most recent of 17 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free